<?xml version='1.0' encoding='utf-8'?>
<document xmlns:codify="http://code.dccouncil.us/schemas/codify" id="D.C. Law 17-131">
  <num type="law">17-131</num>
  <heading type="short">SafeRx Amendment Act of 2008</heading>
  <meta>
    <effective>2008-03-26</effective>
    <cites>
      <law lawId="131" period="17" url="./docs/17-131.pdf"/>
      <register page="1659" vol="55"/>
    </cites>
    <history url="http://lims.dccouncil.us/Legislation/B17-0364">
      <narrative>Law 17-131, the “SafeRx Amendment Act of 2008”, was introduced in Council and assigned Bill No. 17-364 which was referred to the Committee on Health. The Bill was adopted on first and second readings on December 11, 2007, and January 8, 2008, respectively. Signed by the Mayor on February 1, 2008, it was assigned Act No. 17-282 and transmitted to both Houses of Congress for its review. D.C. Law 17-131 became effective on March 26, 2008.</narrative>
    </history>
  </meta>
  <section from-code="true">
    <codify:insert doc="D.C. Code" path="|48|8B"/>
    <num codify:value="48-841.01">201</num>
    <heading>Short title.</heading>
    <text>This chapter may be cited as the “Off-Label Informed Consent Act of 2008”.</text>
    <annotations>
      <annoGroup>
        <heading>History</heading>
        <annotation doc="D.C. Law 17-131">Mar. 26, 2008, D.C. Law 17-131, § 201, 55 DCR 1659</annotation>
      </annoGroup>
      <annoGroup>
        <heading>Delegation of Authority</heading>
        <annotation>Delegation of Authority pursuant to <cite doc="D.C. Law 17-131">D.C. Law 17-131</cite>, the SafeRX Amendment Act of 2008, see Mayor’s Order 2008-94, July 3, 2008 ( 55 DCR 9375).</annotation>
      </annoGroup>
    </annotations>
  </section>
  <section from-code="true">
    <codify:insert doc="D.C. Code" path="|48|8B"/>
    <num codify:value="48-841.02">202</num>
    <heading>Definitions.</heading>
    <text>For the purposes of this chapter, the term:</text>
    <para>
      <num>(1)</num>
      <text>“FDA” means the federal Food and Drug Administration.</text>
    </para>
    <para>
      <num>(2)</num>
      <text>“Off-label use” means the use of a prescription drug for human use to treat a condition that is not included in the labeling for that medication, as approved by the federal Food and Drug Administration.</text>
    </para>
    <para>
      <num>(3)</num>
      <text>“Prescriber” means a person who is licensed, registered, or otherwise authorized by the District to prescribe and administer prescription drugs for human use in the course of a professional practice.</text>
    </para>
    <annotations>
      <annoGroup>
        <heading>History</heading>
        <annotation doc="D.C. Law 17-131">Mar. 26, 2008, D.C. Law 17-131, § 202, 55 DCR 1659</annotation>
        <annotation doc="D.C. Law 17-353">Mar. 25, 2009, D.C. Law 17-353, § 309(b), 56 DCR 1117</annotation>
      </annoGroup>
      <annoGroup>
        <heading>Effect of Amendments</heading>
        <annotation><cite doc="D.C. Law 17-353">D.C. Law 17-353</cite>, in par. (2), substituted “prescription drug for human use” for “prescription drug”; in par. (3), substituted “prescription drugs for human use” for “prescription drugs”.</annotation>
      </annoGroup>
    </annotations>
  </section>
  <section from-code="true">
    <codify:insert doc="D.C. Code" path="|48|8B"/>
    <num codify:value="48-841.03">203</num>
    <heading>Off-label use of medication.</heading>
    <text>Before prescribing, administering, or furnishing a prescription medication for an off-label use, a prescriber shall make every reasonable effort to:</text>
    <para>
      <num>(1)</num>
      <text>Explain to the patient, in easily understood terms, that the medication is not within the uses approved for that medication by the FDA; and</text>
    </para>
    <para>
      <num>(2)</num>
      <text>Provide the patient with information regarding the potential risks and side effects associated with using the medication for the off-label use.</text>
    </para>
    <annotations>
      <annoGroup>
        <heading>History</heading>
        <annotation doc="D.C. Law 17-131">Mar. 26, 2008, D.C. Law 17-131, § 203, 55 DCR 1659</annotation>
      </annoGroup>
      <annoGroup>
        <heading>Section References</heading>
        <annotation>This section is referenced in § <cite path="§48-844.03">48-844.03</cite>.</annotation>
      </annoGroup>
    </annotations>
  </section>
  <section from-code="true">
    <codify:insert doc="D.C. Code" path="|48|8B"/>
    <num codify:value="48-841.04">204</num>
    <heading>Penalties.</heading>
    <text>Failure to comply with this chapter may be used by a health-occupation board as a factor when determining licensure status for a prescriber; provided, that a prescriber shall not be subject to an adverse licensure action if the Board of Medicine determines that the prescribing, administering, or furnishing of the prescription medication for the off-label use was clearly evidence-based and the common practice within the medical community.</text>
    <annotations>
      <annoGroup>
        <heading>History</heading>
        <annotation doc="D.C. Law 17-131">Mar. 26, 2008, D.C. Law 17-131, § 204, 55 DCR 1659</annotation>
      </annoGroup>
    </annotations>
  </section>
  <section from-code="true">
    <codify:insert doc="D.C. Code" path="|48|8C"/>
    <num codify:value="48-842.01">301</num>
    <heading>Short title.</heading>
    <text>This chapter may be cited as the “Medication Advisory Committee Receiving Gifts or Remuneration Prohibition Act of 2008”.</text>
    <annotations>
      <annoGroup>
        <heading>History</heading>
        <annotation doc="D.C. Law 17-131">Mar. 26, 2008, D.C. Law 17-131, § 301, 55 DCR 1659</annotation>
      </annoGroup>
    </annotations>
  </section>
  <section from-code="true">
    <codify:insert doc="D.C. Code" path="|48|8C"/>
    <num codify:value="48-842.02">302</num>
    <heading>Definitions.</heading>
    <text>For the purposes of this chapter, the term:</text>
    <para>
      <num>(1)</num>
      <text>“Medication advisory committee” means any committee or panel that is responsible for making recommendations or decisions regarding a formulary to be used by a health program administered by the government of the District of Columbia.</text>
    </para>
    <para>
      <num>(2)</num>
      <text>“Pharmaceutical company” means any entity that is engaged in, either directly or indirectly, the production, preparation, propagation, compounding, manufacturing, conversion or processing of a drug or biological product, including any person acting as its agent or representative.</text>
    </para>
    <annotations>
      <annoGroup>
        <heading>History</heading>
        <annotation doc="D.C. Law 17-131">Mar. 26, 2008, D.C. Law 17-131, § 302, 55 DCR 1659</annotation>
      </annoGroup>
    </annotations>
  </section>
  <section from-code="true">
    <codify:insert doc="D.C. Code" path="|48|8C"/>
    <num codify:value="48-842.03">303</num>
    <heading>Prohibition on gifts and remuneration.</heading>
    <para>
      <num>(a)</num>
      <text>A pharmaceutical company shall not offer a gift or remuneration of any kind to a member of a medication advisory committee.</text>
    </para>
    <para>
      <num>(b)</num>
      <text>A member of a medication advisory committee shall not accept a gift or remuneration of any kind from a pharmaceutical company.</text>
    </para>
    <para>
      <num>(c)</num>
      <text>Nothing in this section shall prohibit the offering or acceptance of medication samples to members of a medication advisory committee who are licensed physicians engaged in the practice of medicine.</text>
    </para>
    <annotations>
      <annoGroup>
        <heading>History</heading>
        <annotation doc="D.C. Law 17-131">Mar. 26, 2008, D.C. Law 17-131, § 303, 55 DCR 1659</annotation>
      </annoGroup>
      <annoGroup>
        <heading>Section References</heading>
        <annotation>This section is referenced in § <cite path="§48-844.03">48-844.03</cite>.</annotation>
      </annoGroup>
    </annotations>
  </section>
  <section from-code="true">
    <codify:insert doc="D.C. Code" path="|48|8C"/>
    <num codify:value="48-842.04">304</num>
    <heading>Penalties.</heading>
    <text>A violation of this chapter shall be punishable by a fine of $1,000 per violation.</text>
    <annotations>
      <annoGroup>
        <heading>History</heading>
        <annotation doc="D.C. Law 17-131">Mar. 26, 2008, D.C. Law 17-131, § 304, 55 DCR 1659</annotation>
      </annoGroup>
    </annotations>
  </section>
  <section from-code="true">
    <codify:insert doc="D.C. Code" path="|48|8D"/>
    <num codify:value="48-843.01">401</num>
    <heading>Short title.</heading>
    <text>This chapter may be cited as the “Pharmaceutical Education Program Establishment Act of 2008”.</text>
    <annotations>
      <annoGroup>
        <heading>History</heading>
        <annotation doc="D.C. Law 17-131">Mar. 26, 2008, D.C. Law 17-131, § 401, 55 DCR 1659</annotation>
      </annoGroup>
    </annotations>
  </section>
  <section from-code="true">
    <codify:insert doc="D.C. Code" path="|48|8D"/>
    <num codify:value="48-843.02">402</num>
    <heading>Definitions.</heading>
    <text>For the purposes of this chapter, the term “pharmaceutical product” shall have the same meaning as provided in § <cite path="§3-1201.02">3-1201.02</cite>(10A)(B)(iii).</text>
    <annotations>
      <annoGroup>
        <heading>History</heading>
        <annotation doc="D.C. Law 17-131">Mar. 26, 2008, D.C. Law 17-131, § 402, 55 DCR 1659</annotation>
      </annoGroup>
    </annotations>
  </section>
  <section from-code="true">
    <codify:insert doc="D.C. Code" path="|48|8D"/>
    <num codify:value="48-843.03">403</num>
    <heading>Establishment of the Pharmaceutical Education Program.</heading>
    <para>
      <num>(a)</num>
      <text>There is established an evidence-based Pharmaceutical Education Program (“Program”) within the Department of Health. The Program shall:</text>
      <para>
        <num>(1)</num>
        <text>Educate prescribers who participate in the District of Columbia Medicaid program, and other publicly funded, contracted, or subsidized health-care programs, on the therapeutic and cost-effective utilization of pharmaceutical products;</text>
      </para>
      <para>
        <num>(2)</num>
        <text>Inform prescribers about pharmaceutical product marketing practices that are intended to circumvent competition from generic, other therapeutically-equivalent alternatives, or other evidence-based treatment options; and</text>
      </para>
      <para>
        <num>(3)</num>
        <text>Utilize, or incorporate into the Program, other independent educational resources or models proven effective in promoting high-quality, evidenced-based, cost-effective information regarding the effectiveness and safety of pharmaceutical products.</text>
      </para>
    </para>
    <para>
      <num>(b)</num>
      <text>The Program shall be made available to prescribers who do not participate in the District of Columbia Medicaid program or other publicly funded, contracted, or subsidized health-care programs on a subscription basis.</text>
    </para>
    <para>
      <num>(c)</num>
      <text>If approved by the Board of Medicine, the PE program may be used to satisfy continuing education requirements for the practice of medicine.</text>
    </para>
    <annotations>
      <annoGroup>
        <heading>History</heading>
        <annotation doc="D.C. Law 17-131">Mar. 26, 2008, D.C. Law 17-131, § 403, 55 DCR 1659</annotation>
      </annoGroup>
      <annoGroup>
        <heading>Section References</heading>
        <annotation>This section is referenced in § <cite path="§48-844.03">48-844.03</cite>.</annotation>
      </annoGroup>
    </annotations>
  </section>
  <section from-code="true">
    <codify:insert doc="D.C. Code" path="|48|8D"/>
    <num codify:value="48-843.04">404</num>
    <heading>Applicability.</heading>
    <text>This chapter shall apply upon inclusion of its fiscal effect in an approved budget and financial plan.</text>
    <annotations>
      <annoGroup>
        <heading>History</heading>
        <annotation doc="D.C. Law 17-131">Mar. 26, 2008, D.C. Law 17-131, § 404, 55 DCR 1659</annotation>
      </annoGroup>
    </annotations>
  </section>
  <section from-code="true">
    <codify:insert doc="D.C. Code" path="|48|8E"/>
    <num codify:value="48-844.01">501</num>
    <heading>Short title.</heading>
    <text>This chapter may be cited as the “SafeRX Evaluation Act of 2008”.</text>
    <annotations>
      <annoGroup>
        <heading>History</heading>
        <annotation doc="D.C. Law 17-131">Mar. 26, 2008, D.C. Law 17-131, § 501, 55 DCR 1659</annotation>
      </annoGroup>
      <annoGroup>
        <heading>Delegation of Authority</heading>
        <annotation>Delegation of Authority pursuant to <cite doc="D.C. Law 17-131">D.C. Law 17-131</cite>, the SafeRX Amendment Act of 2008, see Mayor’s Order 2008-94, July 3, 2008 ( 55 DCR 9375).</annotation>
      </annoGroup>
    </annotations>
  </section>
  <section from-code="true">
    <codify:insert doc="D.C. Code" path="|48|8E"/>
    <num codify:value="48-844.02">502</num>
    <heading>Definitions.</heading>
    <text>For the purposes of this chapter, the term:</text>
    <para>
      <num>(1)</num>
      <text>“Pharmaceutical product” shall have the same meaning as provided in § <cite path="§3-1201.02">3-1201.02</cite>(10A)(B)(iii).</text>
    </para>
    <para>
      <num>(2)</num>
      <text>“Practice of pharmaceutical detailing” shall have the same meaning as provided in § <cite path="§3-1201.02">3-1201.02</cite>(10A) [§ <cite path="§3-1201.02">3-1201.02</cite>(10A)(A)].</text>
    </para>
    <annotations>
      <annoGroup>
        <heading>History</heading>
        <annotation doc="D.C. Law 17-131">Mar. 26, 2008, D.C. Law 17-131, § 502, 55 DCR 1659</annotation>
      </annoGroup>
    </annotations>
  </section>
  <section from-code="true">
    <codify:insert doc="D.C. Code" path="|48|8E"/>
    <num codify:value="48-844.03">503</num>
    <heading>Evaluation.</heading>
    <para>
      <num>(a)</num>
      <text>Within 60 days of September 30, 2010, the Department of Health shall submit to the Council a comprehensive evaluation on the effectiveness of the SafeRx Amendment Act of 2008, effective March 26, 2008 (<cite doc="D.C. Law 17-131">D.C. Law 17-131</cite>), which shall include:</text>
      <para>
        <num>(1)</num>
        <text>The number of individuals licensed to engage in the practice of pharmaceutical detailing since March 26, 2008;</text>
      </para>
      <para>
        <num>(2)</num>
        <text>The number of applicants for licensure to engage in the practice of pharmaceutical detailing not approved by the Board of Pharmacy;</text>
      </para>
      <para>
        <num>(3)</num>
        <text>The number of applicants for licensure to engage in the practice of pharmaceutical detailing for whom the educational requirements were waived;</text>
      </para>
      <para>
        <num>(4)</num>
        <text>An assessment of the appropriateness and efficacy of the continuing education requirements established pursuant to <cite doc="D.C. Law 17-131">D.C. Law 17-131</cite>;</text>
      </para>
      <para>
        <num>(5)</num>
        <text>The number of individuals identified as engaging in the practice of pharmaceutical detailing without a license;</text>
      </para>
      <para>
        <num>(6)</num>
        <text>The amount of fines levied against persons charged with engaging in the practice of pharmaceutical detailing without a license;</text>
      </para>
      <para>
        <num>(7)</num>
        <text>The total amount and origin of revenue deposited into the Board of Pharmacy Fund;</text>
      </para>
      <para>
        <num>(8)</num>
        <text>The total amount of funds deposited into the Board of Pharmacy Fund that were used for the administration of the duties of the Board of Pharmacy;</text>
      </para>
      <para>
        <num>(9)</num>
        <text>The number and types of penalties levied for failure to comply with the requirements of off-label use of medication as set forth in § <cite path="§48-841.03">48-841.03</cite>;</text>
      </para>
      <para>
        <num>(10)</num>
        <text>The number and amount of fines levied for violations as a result of pharmaceutical companies offering gifts or remuneration in violation of § <cite path="§48-842.03">48-842.03</cite>;</text>
      </para>
      <para>
        <num>(11)</num>
        <text>The number of persons who participated in the Pharmaceutical Education Program established by § <cite path="§48-843.03">48-843.03</cite>;</text>
      </para>
      <para>
        <num>(12)</num>
        <text>An assessment of the quality and effectiveness of the Pharmaceutical Education Program based on an assessment of data gathered from those who participated in the program. The data may be gathered by surveying those who participated in the program, using an evaluative instrument developed for that purpose;</text>
      </para>
      <para>
        <num>(13)</num>
        <text>An assessment of the extent to which regulation of the practice of pharmaceutical detailing has improved the practice of selling, providing information about, or promoting a pharmaceutical product.</text>
      </para>
    </para>
    <para>
      <num>(b)</num>
      <text>The evaluation may be used to determine if <cite doc="D.C. Law 17-131">D.C. Law 17-131</cite> should be repealed or amended.</text>
    </para>
    <annotations>
      <annoGroup>
        <heading>History</heading>
        <annotation doc="D.C. Law 17-131">Mar. 26, 2008, D.C. Law 17-131, § 503, 55 DCR 1659</annotation>
      </annoGroup>
    </annotations>
  </section>
</document>
